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Lymphoepithelioma-like carcinoma (LELC) of the lung, an Epstein–Barr virus-associated undifferentiated
carcinoma, is a rare entity of pulmonary malignancy. It tends to affect young non-smoking Asians and is often
resectable. However, little is known of the treatment of the even rarer locally advanced or metastatic cases. We
report our experience of three Chinese patients with advanced LELC of the lung who were treated with
combination-chemotherapy (5-fluorouracil, leucovorin, and cisplatin) and radiotherapy. The encouraging response
of these patients supports the use of this regime in other patients
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Begin et al. first reported lymphoepithelioma-like
carcinoma (LELC) of the lung in 1987 (1). LELC of the
lung tends to affect young non-smoking patients and the
mean age of affected patients has been reported to be 10
years less than that of other histological types of non-small
cell lung carcinoma in a Taiwanese series (2–4, 8). The mean
age was 48 years in a Hong Kong series (3). There are only
about 30 reported cases in the current literature and three
of the major series were reported from Hong Kong (2–4).
Some studies, largely retrospective pathological series, on
the epidemiology, histopathology and association with
Epstein–Barr virus (EBV) have been reported (2,3,5–12).
It is interesting that, despite being a true neoplasm,
metastatic spreading of LELC is considered exceptionally
rare (1–5). The treatment of LELC is controversial and
there has been no consensus. There has only been one
report on induction chemotherapy (13), another on
postoperative chemotherapy (6), and a few case reports of
postoperative radiotherapy for this rare condition (5,7).
For advanced LELC of the lung, there was only one
reported series in the use of chemoradiotherapy as the
primary form of treatment (4).
We have prospectively studied the effects of systemic
chemotherapy and local radiotherapy in our series ofReceived 14 March 2000 and accepted in revised form 30 March
2000.
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experience and this treatment regime should provide insight
into the treatment of this rare form of pulmonary
malignancy.
Methods
Our centre is a tertiary respiratory referral centre for
treatment of patients with non-small cell carcinoma of the
lung in Hong Kong. Routine investigations performed to
confirm the diagnosis for these patients include chest
radiography, computed tomography (CT) of the thorax
and fibre-optic bronchoscopy. Tissue biopsy was obtained
and always reviewed by a specialist pulmonary pathologist.
In the presence of histological evidence of LELC of the
lung, serum IgA titre for EBV, in situ hybridization (ISH)
for EBV-encoded small nuclear RNA (EBER), endoscopic
examination and biopsy of nasopharynx, and magnetic
resonance imaging (MRI) of the nasopharynx were
performed to exclude nasopharyngeal carcinoma which is
a common EBV-associated cancer in Hong Kong and south
China. Serum IgG levels against the viral capsid antigen
(VCA) of Epstein–Barr virus was determined by using
routine established methodology at the Clinical
Microbiology Laboratory of the University of Hong Kong.
Briefly, IgG against Epstein–Barr VCA was determined by
immunofluorescent technique using fluorescein–isothiocya-
nate-conjugated and heavy chain-specific goat anti-human
sera (Dako, Denmark). Titres were expressed as the
reciprocal of the maximum dilution, which gave a positive
immunofluorescence as described previously (14). ISH for
EBER was performed on representative paran sections of
tumours as described previously (3). Very briefly, digox-
igenin-labelled anti-sense riboprobes were generated by in# 2000 HARCOURT PUBLISHERS LTD
TABLE 1. Patients characteristics and other clinical details
Patient
no.
Gender Age
(years)
Smoke Performance
state (WHO)
Presenting
symptom
Biopsy
site
EBER Stage Metastatic
sites
Response to
chemotherapy
RT Response
to RT
Survival*
(months)
1 M 47 Yes 0 cough LN +ve 3B LN NC Yes PR 13
2 F 39 No 0 cough lung +ve 4 LN, bone PR No NA 5
3 F 38 No 0 cough, haemoptysis lung NA 4 LN, lung PR No NA 4
IgA VCA: immunoglobulin A to EBV viral capsid antigen; EBER: EBV-encoded small nuclear RNA; RT: radiotherapy; LN: lymph node;
NA: not applicable; PR: partial response; NC: no change.
*Survival: from presentation to the time of writing, all surviving at the time of writing.
FIG. 1. Photomicrograph obtained for patient 1 showing
(a) irregular islands of tumour cells in a stroma bearing
numerous inflammatory cells. The tumour cells showed
squamoid features but keratinization or intercellular
bridges were absent (H&E,6250); and (b) in situ
hybridization for EBER showed strong hybridization
signals in all tumour cells but the stroma remained
negative (antisense probe for EBER,6200)
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EBER 1 and 2 genes of the virus. Hybridization signal was
detected by standard immunohistochemical methods, using
anti-digoxigenin monoclonal antibody, biotinylated
secondary antibody, and streptavidin–alkaline phosphatase
complex. Two of our three patients had sucient biopsy
material for ISH, which was positive in both cases.
Chemotherapy for lung LELC constituted four 4-weekly
cycles of 5-fluorouracil (5-FU, 1000mgm72 day71 on day
1 to 4), leucovorin (200mgm72 on day 1 to 4), and cisplatin
(100mgm72 on day 1). Sequential local radiotherapy to
mediastinum, given as 1662?5Gy/fraction, was included
for locally advanced disease. Tumour response was assessed
by thoracic computed tomography. Adverse effects from
chemotherapy were recorded according to the National
Cancer Institute (NCI) Common Toxicity Criteria (CTC).
Results
Three cases (two females, mean age 42 years) of lung LELC
were recruited between July 1998 and June 1999. The
baseline characteristics of the patients are presented in
Table 1. Two were never-smokers and one patient was a
smoker. All cases were in good performance state (WHO 0).
Serum IgA titres to EBV were raised to the upper limit of
detection of our laboratory at 4 1/640 in all three cases.
These remained at the same level throughout the course of
chemotherapy. Two of the patients had adequate biopsy
specimens for detection of EBER which were positive
(Fig. 1). All three patients were given the above standard
chemotherapy (5-FU, leucovorin, and cisplatin) and one
patient was also given sequential radiotherapy. After four
courses of chemotherapy, two patients achieved a partial
response with 4 50% reduction in tumour size on thoracic
CT scanning (Fig. 2). The remaining patient had an
unaltered volume of tumour despite chemotherapy and
was given mediastinal radiotherapy 40Gy (2?5Gy/fraction
for 16 days) which led to a partial response. The
chemotherapy regimes were well tolerated except for
moderately severe vomiting (Table 2). There were no
life-threatening complications. Marked symptomatic
palliation occurred in all three cases. At the time of writing,
the three patients have remained asymptomatic and
survived for 13, 5 and 4 months from presentation.Discussion
Our series of three cases presented with cough or haemop-
tysis in which histological proof of LELC was obtained by
lung or lymph node biopsy. Nasopharyngoscopic biopsy and
FIG. 2. Thoracic computed tomography (CT) of one of the
patients showing (a) a 26265 cm3 lower lobe tumour
and (b) mediastinal lymphadenopathy (arrow) before
treatment with 5-fluorouracil, leucovorin and cisplatin;
and (c) the reduction in tumour bulk after chemotherapy.
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noma. The chemotherapy regime, namely a combination of
5-flurouracil, leucovorin and cisplatin, was effective inshrinking the tumour bulk leading to partial response in
two of the three cases. Sequential radiotherapy in the
remaining case achieved partial response. The good ecacy
of our chemotherapy regime was not accompanied by
significant adverse reactions.
Lymphoepithelioma-like carcinoma is an undifferen-
tiated carcinoma associated with a prominent component
of reactive lymphocytes, macrophages and plasma cells.
The neoplastic cells have syncytial appearance, vesicular
chromatin, distinct nucleoli and occasional spindle cell
growth (2). Some may show differentiated squamoid
features without cellular keratinization or intercellular
bridge formation, and rarely focal glandular arrangement
(3). Primary LELC of the lung is histologically
indistinguishable from the prototypical LELC occurring
in the nasopharynx (2). Therefore, a high index of suspicion
by experienced pulmonary pathologists is required to
diagnose this rare condition which is often done patholo-
gically. Although our patients were symptomatic on
presentation, most of the reported cases were detected on
incidental chest radiographs (1,2,4–7,9,10,12–14). Major
differential diagnoses for LELC are non-Hodgkin’s
lymphoma and metastatic nasopharyngeal carcinoma,
both of which are common among the Chinese (5).
Immunohistochemical staining helps to differentiate lym-
phoma from LELC (15). Endoscopic examination and
random biopsies of nasopharynx, together with computed
tomography or preferably magnetic resonance imaging,
are often necessary to exclude primary nasopharyngeal
carcinoma.
Epstein–Barr virus is associated consistently with LELC
from four anatomic sites, namely, stomach, salivary gland,
lung and thymus. The association of EBV with LELC of
the salivary gland and lung is restricted to Asian patients,
whereas the association of EBV with gastric and thymic
LELC does not appear to have ethnic predisposition (16).
The methods for detection of EBV in LELC include
polymerase chain reaction for EBV DNA, in situ hybridiza-
tion for EBV DNA and RNA, and immunohistochemistry
for EBV-associated protein (3,12,17). The hypothesis of
EBV infection preceding the clonal expansion of LELC has
been substantiated by Southern-blot analysis for the
presence of episomal EBV in the tumour tissue (18). Our
cases demonstrate elevated serum titre for EBV-VCA IgA
and positive ISH for EBER in the tumour cells, which are
consistent with previous reports among Asians. However,
the serum titre for EBV-VCA IgA remained elevated
despite response to chemotherapy or radiotherapy in all
three cases.
The few available case reports appear to suggest that
LELC of the lung may be curable by resection, which is the
recommended treatment of choice. In one series of five
cases of resectable LELC, all survived at the time of
writing, three for longer than 60 months, one 45 months,
and one 38 months after surgery (9). In some cases,
postoperative radiotherapy was also given (1,5,7).
Postoperative chemotherapy with four cycles of carbopla-
tinum and VP-16 had been used for stage II LELC of the
lung in one report (6). There was one report of the use of
induction chemotherapy consisting of 5-fluorouracil,
TABLE 2. Adverse effects associated with administration of chemotherapy regime (5-flurouracil, leucovorin and cisplation)
Patient no. Adverse effects (grade)
Neutropenia Thrombocytopenia Infection Vomiting Alopecia Stomatitis
1 1 0 0 2 1 3
2 1 1 0 3 1 2
3 1 0 0 2 1 2
All adverse graded according to NIC common Toxicity Criteria
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resulting in significant tumour reduction (13). In a series of
advanced LELC of the lung treated with palliative
chemotherapy comprised of 5-fluorouracil and cisplatin,
71?4% of patients had a partial response and 28?6% had
progressive disease (4). The addition of leucovorin to
5-fluorouracil, as in our chemotherapy regimen, has been
shown to enhance the effect of 5-fluorouracil (19,20). As
nasopharyngeal carcinoma has similar clinical and biologi-
cal profiles to LELC, the response of the latter to
chemotherapy regimen with 5-fluorouracil, leucovorin and
cisplatin is not surprising (21). Interestingly, myelotoxicity
is commonly associated with bolus administration of 5-
fluorouracil and stomatitis is more frequent with prolonged
continuous infusion (21). Our experience with chemora-
diotherapy in the three cases showed a partial response rate
of 67% (2/3) and one patient achieved a partial response to
radiotherapy. The chemotherapy regime was well tolerated
with no life-threatening adverse effects in our series. Based
on these results, we would recommend future use of
combination chemotherapy (5-FU, leucovorin and cispla-
tin) in advanced LELC of the lung with additional
sequential radiotherapy in locally advanced disease. Newer
chemotherapeutic agents, such as paclitaxel and carbopla-
tin, have also been used in the treatment of advanced
nasopharyngeal carcinoma with encouraging results
(22,23). As formal clinical trials are dicult to conduct
for rare diseases such as LELC, we hope advances in the
management of nasopharyngeal carcinoma would further
enlighten us on the treatment of LELC in the future.
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